Acute myelogenous leukemia C92.0
Conditions
Interventions
Group 1: Data Registration of all childhood AML-cases
Sponsors
GPOH gemeinnützige GmbH,AML-BFM Studienzentrale
Eligibility
Sex/Gender
All
Age
0 Years to 18 Years
Inclusion criteria
Inclusion criteria: • Age 0 - <18 years • de novo AML, Myeloid sarcoma, Acute Mixed Lineage Leukemia/ bi-phenotypic Leukemia (dominant myeloid acc. to WHO 2008) or • AML as secondary malignant tumor or • Transient Leukemias and Myeloid Leukemia in Trisomy 21 or • Relapsed/refractory AML in children and adolescents or • “Special" cases of AML-associated diseases after consultation with and approval by the Register chair • Admission to an accredited pediatric oncology center acc. to GBA resolution “Pediatric Oncology” • Existence of all necessary Informed Consent Forms
Exclusion criteria
Exclusion criteria: • Missing Informed Consent Forms oft he patient and/or his/her legal representative
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Registration of all AML diseases and their treatment in children and adolescents in the participating centers of all participating countries | — |
Secondary
| Measure | Time frame |
|---|---|
| 2. Registration of genetic, molecular genetic and epigenetic characteristics of AML in children and adolescents 3. Determination of minimal residual disease (MRD) via morphology, immunophenotyping and molecular genetic 4. Registration of the frequency and kinetic of a molecular relapse | — |
Countries
Austria, Czechia, Germany, Slovakia, Switzerland
Contacts
Public ContactReinhardt Dirk
AML-BFM studiengruppe, Universitätskinderklinik III
Outcome results
None listed